Company intelligence / Profile preview

Solstic Medicine

Cambridge, Massachusetts, United States

Ownership: Private
Employees: ~15
Development stage: Other

Overview

Solstic Medicine is a pre-clinical stage biotechnology company focused on developing precision therapies for autoimmune and inflammatory diseases by targeting the solute carrier (SLC) family of transporters. The company's lead program focuses on inhibiting SLC15A4, a key regulator of endosomal toll-like receptor signaling and lysosomal function in immune cells. By modulating these specific transport mechanisms, Solstic aims to provide highly targeted treatments for conditions such as systemic lupus erythematosus and inflammatory bowel disease. The company was founded by industry veterans and is backed by prominent life science venture capital firms.

Therapeutic areas: ImmunologyGastroenterology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Solstic Medicine.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Solstic Medicine.

Explore the full profile